共 149 条
[1]
Kranzer K(2012)Quantifying and addressing losses along the continuum of care for people living with HIV infection in sub-Saharan Africa: a systematic review J Int AIDS Soc 15 119-116
[2]
Govindasamy D(2010)Incident Tuberculosis during Antiretroviral Therapy Contributes to Suboptimal Immune Reconstitution in a Large Urban HIV Clinic in Sub-Saharan Africa PLoS ONE 5 349-355
[3]
Ford N(2011)Tuberculosis in patients receiving antiretroviral treatment: incidence, risk factors, and prevention strategies J Acquir Immune Defic Syndr 56 2121-2133
[4]
Johnston V(2013)Prevalent and incident tuberculosis are independent risk factors for mortality among patients accessing antiretroviral therapy in South Africa PLoS One 8 e515-e523
[5]
Lawn SD(2012)Reducing deaths from tuberculosis in antiretroviral treatment programmes in sub-Saharan Africa AIDS. 26 103-1197
[6]
Hermans SM(2018)Sensitivity and specificity of WHO's recommended four-symptom screening rule for tuberculosis in people living with HIV: a systematic review and meta-analysis Lancet HIV 5 53-301
[7]
Kiragga AN(2012)Point-of-care detection of lipoarabinomannan (LAM) in urine for diagnosis of HIV-associated tuberculosis: a state of the art review BMC Infect Dis 12 1187-e1000399
[8]
Schaefer P(2016)Detection of lipoarabinomannan (LAM) in urine is an independent predictor of mortality risk in patients receiving treatment for HIV-associated tuberculosis in sub-Saharan Africa: a systematic review and meta-analysis BMC Med 14 292-e0156812
[9]
Kambugu A(2016)Effect on mortality of point-of-care, urine-based lipoarabinomannan testing to guide tuberculosis treatment initiation in HIV-positive hospital inpatients: a pragmatic, parallel-group, multicountry, open-label, randomised controlled trial Lancet. 387 e1000391-e1002717
[10]
Hoepelman AIM(2018)Rapid urine-based screening for tuberculosis in HIV-positive patients admitted to hospital in Africa (STAMP): a pragmatic, multicentre, parallel-group, double-blind, randomised controlled trial Lancet. 392 e006833-587